TechnoVax, Inc.
About Us Technologies Services Media Presentación en Español  

Manufacturing

 
  VLP Vaccine Technology
  Manufacturing
  Market Opportunities
  Competition
  Pipeline
  Intellectual Property

Production of Influenza Vaccine:

Differences Between Current Process and VLP Technology

 

Current Process

  • Virus grown in embryonated chicken eggs
  • Killed vaccine requires chemical inactivation
  • Live attenuated vaccine requires extensive safety evaluation
  • HPAI viruses (i.e. 1918, H5) kill the chicken embryo and prevent vaccine production
  • Slow process when possible

VLP Technology

  • VLP produced in cultured cells
  • VLPs are non-infectious, inactivation is not required
  • Less safety concerns during production
  • VLP for HPAI viruses can be produced safely
  • VLP production is more rapid
  • TechnoVax production time is 3-4 months
 
 

Robust Cell-based System for Large Scale Manufacturing

  • VLP vaccines can be made in a continuous cell-culture system, which is rapidly scalable for large volume manufacturing.
  • VLP vaccines are purified from the culture medium and inactivation is not required, because VLP vaccines are not infectious.
  • Fast and flexible system for rapid response to emerging pandemic or epidemic influenza virus strains.
  • High yield, larger production capabilities, shorter production time and lower cost.

 
Home Contact Us

Copyright © 2003-2009 TechnoVax. All rights reserved.   •   Website by AJ Network Solutions